TransCode Therapeutics, Inc.

NasdaqCM:RNAZ Stock Report

Market Cap: US$1.9m

TransCode Therapeutics Management

Management criteria checks 4/4

TransCode Therapeutics' CEO is Tom Fitzgerald, appointed in Jul 2018, has a tenure of 6.5 years. total yearly compensation is $426.86K, comprised of 83.9% salary and 16.1% bonuses, including company stock and options. directly owns 0.008% of the company’s shares, worth $156.55. The average tenure of the management team and the board of directors is 6.5 years and 6.3 years respectively.

Key information

Tom Fitzgerald

Chief executive officer

US$426.9k

Total compensation

CEO salary percentage83.9%
CEO tenure6.5yrs
CEO ownership0.008%
Management average tenure6.5yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

TransCode Therapeutics reports Q2 results

Aug 15

TransCode files U.S. patent application for radiotherapy based cancer treatment

Jul 11

We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely

Apr 01
We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation

Dec 15
Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation

CEO Compensation Analysis

How has Tom Fitzgerald's remuneration changed compared to TransCode Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$15m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$17m

Dec 31 2023US$427kUS$358k

-US$19m

Sep 30 2023n/an/a

-US$20m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$19m

Dec 31 2022US$561kUS$371k

-US$18m

Sep 30 2022n/an/a

-US$15m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$6m

Dec 31 2021US$318kUS$180k

-US$7m

Sep 30 2021n/an/a

-US$5m

Jun 30 2021n/an/a

-US$4m

Mar 31 2021n/an/a

-US$7m

Dec 31 2020US$15kn/a

-US$2m

Compensation vs Market: Tom's total compensation ($USD426.86K) is below average for companies of similar size in the US market ($USD642.68K).

Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.

CEO

Tom Fitzgerald (72 yo)

6.5yrs

Tenure

US$426,862

Compensation

Mr. Thomas A. Fitzgerald, also known as Tom, M.B.A. has been the Director of TransCode Therapeutics Inc. since July 2018. He serves as Chief Financial Officer at TransCode Therapeutics, Inc. since July 201...

Leadership Team

NamePositionTenureCompensationOwnership
Philippe Calais
Executive Chairman of the Board6.3yrsUS$112.61k0.00096%
$ 18.3
Thomas Fitzgerald
Interim CEO6.5yrsUS$426.86k0.0082%
$ 156.5
Zdravka Medarova
Co-Founder & Chief Scientific Officer9yrsno datano data
Anna Moore
Co-Founder9yrsno datano data
Susan Duggan
Senior Vice President of Operationsno datano datano data
Daniel Vlock
Chief Medical Officerless than a yearno datano data

6.5yrs

Average Tenure

65yo

Average Age

Experienced Management: RNAZ's management team is seasoned and experienced (6.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Philippe Calais
Executive Chairman of the Board6.3yrsUS$112.61k0.00096%
$ 18.3
Thomas Fitzgerald
Interim CEO6.5yrsUS$426.86k0.0082%
$ 156.5
Anna Moore
Co-Founder9yrsno datano data
John Henneman
Member of Advisory Boardno datano datano data
G. Srivatsa
Member of Advisory Boardno datano datano data
Magda Marquet
Independent Director4yrsUS$75.11k0%
$ 0
Dmitry Samarsky
Member of Advisory Boardno datano datano data
Keith Flaherty
Member of Advisory Boardno datano datano data
Raul Mostoslavsky
Member of Advisory Boardno datano datano data
George Calin
Member of Advisory Boardno datano datano data
Raghu Kalluri
Member of Advisory Boardno datano datano data
Erik Manting
Independent Director4.1yrsUS$73.11k0%
$ 0

6.3yrs

Average Tenure

62yo

Average Age

Experienced Board: RNAZ's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 11:53
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TransCode Therapeutics, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarH.C. Wainwright & Co.